These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25316297)

  • 1. Mismatch between perfusion and metabolism in locally advanced breast cancer.
    Evangelista L; Cervino AR
    Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):803-4. PubMed ID: 25316297
    [No Abstract]   [Full Text] [Related]  

  • 2. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.
    Yoon HJ; Kang KW; Chun IK; Cho N; Im SA; Jeong S; Lee S; Jung KC; Lee YS; Jeong JM; Lee DS; Chung JK; Moon WK
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1534-43. PubMed ID: 24652232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of 6 common antigenic markers in invasive ductal breast carcinoma: potential clinical implications.
    Lialiaris TS; Kouskoukis A; Georgiou G; Tripsianis G; Fiska A; Giatromanolaki A; Chrisafi S; Sivridis E; Vamvakopoulou DN; Soutopoulou DO; Kiritsaka A; Athanassiou E; Lialios GA; Sotiriou S; Sidiropoulos A; Vamvakopoulos NC
    Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):106-11. PubMed ID: 20724920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delay to formalin fixation effect on breast biomarkers.
    Khoury T; Sait S; Hwang H; Chandrasekhar R; Wilding G; Tan D; Kulkarni S
    Mod Pathol; 2009 Nov; 22(11):1457-67. PubMed ID: 19734848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The glycomic profile of invasive ductal carcinoma of the breast is altered in patients with hypoxic regions: implications for tumor behavior.
    Rêgo MJ; da Silva Filho AF; Cordeiro MF; Santos PB; Beltrão EI
    Folia Histochem Cytobiol; 2014; 52(2):96-103. PubMed ID: 25007177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients.
    Pape-Zambito D; Jiang Z; Wu H; Devarajan K; Slater CM; Cai KQ; Patchefsky A; Daly MB; Chen X
    PLoS One; 2014; 9(6):e100488. PubMed ID: 24978026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast.
    Xu R; Feiner H; Li P; Yee H; Inghirami G; Delgado Y; Perle MA
    Arch Pathol Lab Med; 2003 Nov; 127(11):1458-64. PubMed ID: 14567723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schirrous invasive ductal carcinoma of the breast overexpress p53 oncoprotein.
    Ferrini FS; Rossi MA; Neto MM; Soares FA
    Sao Paulo Med J; 2001 Jan; 119(1):4-6. PubMed ID: 11175617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An analysis of predictive biomarkers in routine histopathological reporting of infiltrating ductal breast carcinoma in a tertiary hospital in Malaysia with a focus on limitations and directions for future development.
    Teoh KH; Looi LM; Sabaratnam S; Cheah PL; Nazarina AR; Mun KS
    Malays J Pathol; 2011 Jun; 33(1):35-42. PubMed ID: 21874750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P53, c-erbB-2 expression and steroid hormone receptors in breast carcinoma: correlations with histopathological parameters.
    Kilinç N; Yaldiz M
    Eur J Gynaecol Oncol; 2004; 25(5):606-10. PubMed ID: 15493177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 8 in progression of hormone-dependent early breast cancer.
    Milovanovic J; Todorovic-Rakovic N; Vujasinovic T; Abu Rabi Z
    J Biosci; 2017 Jun; 42(2):265-274. PubMed ID: 28569250
    [No Abstract]   [Full Text] [Related]  

  • 12. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
    Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
    Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast carcinoma in Uganda: microscopic study and receptor profile of 45 cases.
    Roy I; Othieno E
    Arch Pathol Lab Med; 2011 Feb; 135(2):194-9. PubMed ID: 21284437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytologic atypia in the contralateral unaffected breast is related to parity and estrogen-related genes.
    Monahan DA; Wang J; Lee O; Revesz E; Taft N; Ivancic D; Hansen NM; Bethke KP; Zalles C; Khan SA
    Surg Oncol; 2016 Dec; 25(4):449-456. PubMed ID: 26856771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An unusual triple-negative breast carcinoma.
    Shousha S; Peston D; Gojis O; Palmieri C
    Histopathology; 2009 Sep; 55(3):364-6. PubMed ID: 19723156
    [No Abstract]   [Full Text] [Related]  

  • 16. Expression of androgen receptor in breast cancer and its significance as a prognostic factor.
    Yu Q; Niu Y; Liu N; Zhang JZ; Liu TJ; Zhang RJ; Wang SL; Ding XM; Xiao XQ
    Ann Oncol; 2011 Jun; 22(6):1288-1294. PubMed ID: 21109569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors.
    Truin W; Roumen RMH; Siesling S; van de Vijver KK; Tjan-Heijnen VCG; Voogd AC
    Breast Cancer Res Treat; 2017 Jul; 164(1):133-138. PubMed ID: 28365833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [C-erbB-2 oncogene amplification in breast cancer in correlation to steroid and epidermal growth factor receptor].
    Manavi M; Czerwenka KF; Zeillinger R; Speiser P; Kury F; Steinhart U; Peschke M; Kubista E; Reinold E
    Zentralbl Gynakol; 1992; 114(2):82-5. PubMed ID: 1350129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of cancer-testis antigen CT7 (MAGE-C1) in breast cancer: an immunohistochemical study with emphasis on prognostic utility.
    Krüger S; Ola V; Feller AC; Fischer D; Friedrich M
    Pathol Oncol Res; 2007; 13(2):91-6. PubMed ID: 17607369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer.
    Tapia C; Zlobec I; Schneider S; Kilic E; Güth U; Bubendorf L; Kim S
    Hum Pathol; 2011 Jul; 42(7):983-90. PubMed ID: 21315418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.